Transcatheter aortic valve replacement (TAVR) for the treatment of congenital heart disease has been mostly limited to patients with bicuspid aortic valve stenosis. We present a case of a 19 year old Jehovah's witness patient with D-Transposition of the great arteries (D-TGA) who underwent an arterial switch operation, followed by a valve sparing aortic root repair with a hemashield graft, who later developed severe aortic valve regurgitation and successfully underwent a transcatheter aortic valve replacement (TAVR) with the Edwards Sapien-3 valve.
replacement. TAVR has had limited application in the ACHD population to this point, mostly utilized for the treatment of bicuspid aortic valve (BAV) stenosis or valve-in-valve replacement of dysfunctional aortic bioprostheses. Aortic stenosis or aortic regurgitation (AR) in ACHD patients may be due to isolated valvular abnormality such as BAV or as a component of additional congenital anomalies such as hypoplastic left heart syndrome. Both aortic stenosis and AR can occur following aortic valve repair or replacement with bioprostheses, homografts, or pulmonary autografts as in the Ross procedure or in arterial switch operations. We herein present a case of TAVR in an ACHD patient with D-transposition of the great arteries (D-TGA) post status arterial switch and subsequent valve sparing aortic root repair with resultant severe AR.
Introduction
The minimally invasive technique of transcatheter aortic valve replacement (TAVR) may be ideal for the growing population of adult congenital heart disease (ACHD) patients, many of whom may be at increased risk of adverse events associated with surgical valve al and ventricular septal defect closure at 2 years of age; and valve-sparing aortic root replacement with a 22-mm Hemashield graft and subaortic membrane resection at 15 years of age. The last operation was complicated by cognitive injury and memory loss, and her recovery was protracted. She subsequently developed symptomatic severe AR. Because of her refusal to receive blood transfusions due to her Jehovah's Witness faith and history of three surgeries, two median sternotomies, and post-operative cognitive injury, she was considered high risk for repeat surgical intervention and was referred for off-label use of TAVR. 
Procedure
Pre-procedural electrocardiography-gated cardiac computed tomographic angiography (CTA) showed the valve annular dimensions to be 21 × 20 × 23 mm, adequate clearance of the coronary ostia to the annulus, and no aortic valve or ascending aortic calcification. Abdominal/pelvic CTA demonstrated adequate femoral arterial size for a transfemoral valve replacement approach without significant tortuosity.
The procedure was performed under general anesthesia. Intra-procedural transesophageal echocardiography (TEE) showed severe eccentric aortic regurgitation due to malcoaptation of the aortic valve leaflets and prominent prolapse of the left coronary cusp leaflet ( Figure 1 ; Videos 1, 2, 3, and 4). There was a false chord extending from the anterior mitral valve leaflet to the left ventricular outflow tract without functional obstruction (Video 2). The aortic valve annulus measured 20 × 20 × 21 mm by TEE, mostly consistent with the CTA annular dimensions. Aortic root angiograms (Figure 2 ; Video 5) showed severe AR and patent re-implanted coronary arteries without evidence of atherosclerotic disease with a distance from the valve level of 27-30 mm and minimal concern for coronary obstruction. A 23 mm × 4 cm balloon was used to perform balloon sizing with rapid ventricular pacing at 180 bpm; the waist on the balloon was noted to be 21 mm. A 26-mm Edwards Sapien-3 valve (Edwards LifeSciences, Irvine, CA, USA) was prepped and mounted onto the Commander delivery system in the usual manner and advanced into the 14-F sheath, and the valve was assembled in the descending aorta. Once across the valve, aortic angiography was performed to ensure appropriate position of the Sapien valve. Rapid pacing at 180 bpm was initiated, and the valve was deployed using the nominal volume of 23 ml (Video 6). Aortic root angiography was performed, which demonstrated a competent aortic valve (Figure 2; Video 7) . Post-deployment TEE showed a well-positioned 26-mm Edwards Sapien-3 valve with trace perivalvular regurgitation at the left coronary cusp region and no central regurgitation (Figure 1 ; Videos 8 and 9). The delivery sheath was pulled and perclose sutures were deployed; however, right iliac angiography revealed that the right femoral artery was occluded at the site of the perclose su- the next few months following the initial TAVR, the patient reported worsening exertional symptoms. Given the perivalvular AR, she was brought back to the cardiac catheterization laboratory. Cineangiography demonstrated slight downward migration of the aortic prosthesis with evidence of severe perivalvular regurgitation (Figure 4; Video 12 ). This was hypothesized to be due to inadequate post-dilation of the Sapien valve in a patient with primary AR. A 24-mm Vida balloon (BARD Peripheral Vascular, Tempe, AZ, USA) was used to perform high-pressure dilation, which resulted in improved valve apposition to the walls of the hemashield graft and resolution of the perivalvular AR (Figure 4; Videos 13 and 14) . The patient toler-tures. Surgical cutdown and open repair of the right femoral artery were performed with a good final result and return of normal peripheral pulses.
The patient was monitored in the surgical intensive care unit. Her B-natriuretic peptide level decreased from 121 pg/ml pre-procedure to 39 pg/ ml. Her post-operative echocardiogram showed no evidence of central or perivalvular regurgitation. She was started on aspirin and clopidogrel and discharged on postoperative day 2. On initial clinic follow-up within 1 month post-procedure, she reported minimal improvement in her exertional symptoms, and her echocardiogram showed progressive perivalvular regurgitation (Figure 3 ; Videos 10 and 11). In pien-3 (Edwards Lifesciences), which have a sealing system that decreases perivalvular regurgitation [2] . Nevertheless, the use of TAVR in the ACHD population has been scant, and many patients present with predominant AR without calcification. The present case illustrates the benefits and potential pitfalls of TAVR in an ACHD patient with primary AR. Although the hemashield graft served as an anchor for valve deployment well below the coronary artery buttons, there was evidence of gradual downward migration and development of severe perivalvular regurgitation despite initial valve placement at nominal balloon volume, indicating a potential role for deployment at greater than nominal volumes and the importance of adequate post-dilation. Several newer generation transcatheter valves are currently in preclinical or ear-ated the procedure well, and follow-up echocardiography 4 months post-procedure demonstrated mild perivalvular regurgitation and stable valve position (Figure 3 ; Videos 15 and 16).
Discussion
TAVR in the ACHD population has been mostly limited to patients with calcific stenotic BAV. Initially, some studies showed a higher risk of perivalvular regurgitation in BAV TAVR with earlier generation valves including the CoreValve (Medtronic Inc, Minneapolis, MN, USA) and Sapien XT (Edwards Lifesciences) [1] . In later studies, however, this risk was mitigated with the use of newer generation valves such as the Lotus (Boston Scientific, Marlborough, MA, USA) and Sa- niques have allowed for a reduction in the number of open cardiac surgeries needed over the lifetime of a CHD patient. Advances in technology are increasing the applications of TAVR in lesions that were previously only surgically treated. TAVR in ACHD patients with predominant AR is a new frontier, and the use of the newer-generation valves may prove promising.
